Editing Neucruit
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then publish the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 1: | Line 1: | ||
{{Cover Image|[[File:Neucruit Thesis cover image.jpg]]}} | {{Cover Image|[[File:Neucruit Thesis cover image.jpg]]}} | ||
'''About Neucruit:''' | |||
Neucruit is a B2B solution for innovators bringing life- saving medications to market. We connect innovators with patients at scale, making clinical research accessible to patients by reaching them through conversations on their native channels. Our solution combines data and creativity to reach, qualify and register patients to clinical studies. | Neucruit is a B2B solution for innovators bringing life- saving medications to market. We connect innovators with patients at scale, making clinical research accessible to patients by reaching them through conversations on their native channels. Our solution combines data and creativity to reach, qualify and register patients to clinical studies. | ||
'''Neucruit’s vision:''' | |||
A world where everyone is involved in their healthcare discoveries. | A world where everyone is involved in their healthcare discoveries. | ||
'''Status on current round:''' | |||
Seeking to raise £1.5M for an 18-month runway. | Seeking to raise £1.5M for an 18-month runway. | ||
Line 10: | Line 15: | ||
<youtube>9mn1KsBaDi0</youtube> | <youtube>9mn1KsBaDi0</youtube> | ||
==Investment Interview | ==Investment Interview== | ||
'''Explain what your venture does.''' | '''Explain what your venture does.''' | ||
Line 63: | Line 68: | ||
In pipeline: - Completed COVID-19 clinical trial and obesity clinical trial, over 90% in timeline reduction for both - Growing community of emerging biotechs to convert for deals ranging from 25,00 GBP, 20% increase week-on-week - Signed CDA’s with Syneos Health and Covance for deals ranging from 100,000 GBP. | In pipeline: - Completed COVID-19 clinical trial and obesity clinical trial, over 90% in timeline reduction for both - Growing community of emerging biotechs to convert for deals ranging from 25,00 GBP, 20% increase week-on-week - Signed CDA’s with Syneos Health and Covance for deals ranging from 100,000 GBP. | ||
[[Category:Thesis]] | [[Category:Thesis]] | ||
[[Category:Equities]] | [[Category:Equities]] | ||
__INDEX__ | __INDEX__ |